Maintenance Therapy Post-Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2024 Oct 25

PMID 39451755

Authors

Martina Canichella

Matteo Molica

Carla Mazzone

Paolo de Fabritiis

Affiliations

Soon will be listed here.

Abstract

High-risk acute myeloid leukemia has been associated with a poor outcome. Hematopoietic stem cell transplantation (HSCT) represents the only curative option for eligible patients. Relapse after HSCT is a dramatic event with poor chances of survival. With the aim of reducing the rate of post-HSCT relapse, maintenance treatment has been investigated in this setting. Results from clinical trials suggest an advantage in the use of a maintenance strategy; however, standardized guidelines are not yet available due to the lack of prospective clinical trials. In this review, we have reported the most important strategies adopted as post-HSCT maintenance, highlighting their efficacy, but the current research also opens questions.

References

Lindsley R, Saber W, Mar B, Redd R, Wang T, Haagenson M . Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med. 2017; 376(6):536-547. PMC: 5438571. DOI: 10.1056/NEJMoa1611604. View

Wei A, Strickland Jr S, Hou J, Fiedler W, Lin T, Walter R . Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. J Clin Oncol. 2019; 37(15):1277-1284. PMC: 6524989. DOI: 10.1200/JCO.18.01600. View

Jedlickova Z, Schmid C, Koenecke C, Hertenstein B, Baurmann H, Schwerdtfeger R . Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation. Bone Marrow Transplant. 2015; 51(5):663-7. DOI: 10.1038/bmt.2015.234. View

Liu W, Zhou Z, Chen L, Wang X . Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis. Clin Lymphoma Myeloma Leuk. 2021; 21(6):e530-e544. DOI: 10.1016/j.clml.2021.01.024. View

DiNardo C, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T . Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015; 90(8):732-6. PMC: 4612499. DOI: 10.1002/ajh.24072. View

Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik V, Paschka P, Roberts N . Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016; 374(23):2209-2221. PMC: 4979995. DOI: 10.1056/NEJMoa1516192. View

Molica M, Breccia M, Foa R, Jabbour E, Kadia T . Maintenance therapy in AML: The past, the present and the future. Am J Hematol. 2019; 94(11):1254-1265. DOI: 10.1002/ajh.25620. View

Mathew N, Baumgartner F, Braun L, OSullivan D, Thomas S, Waterhouse M . Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018; 24(3):282-291. PMC: 6029618. DOI: 10.1038/nm.4484. View

Cauchois R, Castagna L, Pagliardini T, Harbi S, Calmels B, Bramanti S . Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3 cells. Br J Haematol. 2018; 185(3):570-573. DOI: 10.1111/bjh.15544. View

10.

Legrand F, Le Floch A, Granata A, Furst S, Faucher C, Lemarie C . Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML. Bone Marrow Transplant. 2016; 52(4):620-621. DOI: 10.1038/bmt.2016.326. View

11.

Schmid C, Labopin M, Schaap N, Veelken H, Schleuning M, Stadler M . Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT. Br J Haematol. 2018; 184(5):782-787. DOI: 10.1111/bjh.15691. View

12.

Antar A, Otrock Z, Jabbour E, Mohty M, Bazarbachi A . FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. Leukemia. 2020; 34(3):682-696. DOI: 10.1038/s41375-019-0694-3. View

13.

Parks K, Diebold K, Salzman D, Di Stasi A, Al-Kadhimi Z, Espinoza-Gutarra M . Low-dose decitabine plus venetoclax as post-transplant maintenance for high-risk myeloid malignancies. EJHaem. 2024; 5(3):560-564. PMC: 11182382. DOI: 10.1002/jha2.915. View

14.

Wei Y, Xiong X, Li X, Lu W, He X, Jin X . Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome. Cancer Sci. 2021; 112(9):3636-3644. PMC: 8409404. DOI: 10.1111/cas.15048. View

15.

Dohner H, Wei A, Appelbaum F, Craddock C, DiNardo C, Dombret H . Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12):1345-1377. DOI: 10.1182/blood.2022016867. View

16.

Pagliuca S, Schmid C, Santoro N, Simonetta F, Battipaglia G, Guillaume T . Donor lymphocyte infusion after allogeneic haematopoietic cell transplantation for haematological malignancies: basic considerations and best practice recommendations from the EBMT. Lancet Haematol. 2024; 11(6):e448-e458. DOI: 10.1016/S2352-3026(24)00098-X. View

17.

Kent A, Schwartz M, McMahon C, Amaya M, Smith C, Tobin J . Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse. Bone Marrow Transplant. 2023; 58(8):849-854. DOI: 10.1038/s41409-023-01987-5. View

18.

Snowden J, Sanchez-Ortega I, Corbacioglu S, Basak G, Chabannon C, de la Camara R . Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant. 2022; 57(8):1217-1239. PMC: 9119216. DOI: 10.1038/s41409-022-01691-w. View

19.

Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A . Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2011; 26(3):381-9. PMC: 3306138. DOI: 10.1038/leu.2011.234. View

20.

Schmid C, Kuball J, Bug G . Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies. J Clin Oncol. 2021; 39(5):397-418. DOI: 10.1200/JCO.20.01719. View